Merck Sharpe & Dohme has indicated that the future of rofecoxib (Vioxx),the cyclo-oxygenase-2 (COX-2) inhibitor withdrawn from the market last year (PJ,9 October 2004,p505),is still open to consideration.Although the company says that it stands by the voluntary withdrawal of the drug,Peter Kim,president of Merck Research Laboratories in the US,has suggested that the company will take account of emerging data on other therapies within the COX-2 class.
展开▼
